Introduction {#S6}
============

The prevalence of severe obesity has increased dramatically over the past four decades, resulting in increased mortality and higher prevalence of medical comorbidities including type-2 diabetes and heart disease,^[@R1]^ Obesity is also associated with poor neurocognitive outcomes.^[@R2]^ We previously found that elevated BMI is not only associated with cognitive deficits in adults with obesity,^[@R3]^ but also that weight loss with bariatric surgery leads to cognitive improvements.^[@R4]^ Yet, the pathophysiological bases for these adverse effects of obesity are clearly understood. Elevated BMI alone is associated with reduced cognitive performance when examined in the context of otherwise healthy community samples.^[@R5]^ However, cognitive dysfunction also occur secondarily among adults with medical disorders including type-2 diabetes,^[@R6]^ hypertension,^[@R7]^ and other vascular etiologies and risk factors.^[@R8],[@R9]^ It is also common in obstructive sleep apnea (OSA),^[@R10]^ which is highly related to obesity and can be partially reversed with continuous positive airway pressure (CPAP) therapy.^[@R11]^

Evidence of interactions between cognition and health-related factors, including hypertension and diabetes,^[@R12]^ are important to consider given high prevalence of concurrent medical comorbidities in adults with chronic obesity. Although an interactive effect is not ubiquitous,^[@R13]^ diabetes commonly exacerbates adverse effects of elevated BMI on cognition and the brain.^[@R14]^ Yet, studies often control for diabetes with minimal consideration for interactive effects with obesity.^[@R15]^

Obesity-associated neuroinflammation can also contribute to cognitive decline, though exact mechanisms are not clear.^[@R16]^ Vascular etiologies in conjunction with obesity can also exacerbate cognitive deficits. Among patients with heart failure, both hypertension and obesity contributed to worse performance in attention, executive functions, and language.^[@R17]^ However, others have shown a less consistent impact for obesity with systematic comparison of vascular risk factors.^[@R8],[@R18]^ Studies examining associations between obesity and other comorbidities on cognition have also yielded mixed results. We previously found that cognitive improvements associated with weight loss surgery were not attributable to reduced OSA.^[@R19]^ Despite research to support cognitive deficits secondary to OSA, disentangling the influence of obesity *per se* remains a challenge.^[@R20]^

While it is not surprising that comorbidities such as hypertension and diabetes are independently associated with cognitive deficits, and all are more prevalent among adults with elevated BMI,^[@R18]^ few studies have examined the influence of multiple medical comorbidities and severe obesity on cognitive function. Many studies are often epidemiological analyses of the general population, healthy community cohorts, or individuals with health conditions of wide-ranging severity. Unfortunately, such findings do not directly explain the reason for previously observed cognitive deficits among individuals with severe obesity. Several possibilities exist: 1) Cognitive deficits may be a manifestation of obesity itself; 2) All of the comorbidities common with obesity may interact and contribute to cognitive deficits; or 3) The presence of a specific obesity-associated comorbidity is the primary factor driving cognitive deficits among some, but not all individuals with obesity. To address this issue, the current study examined associations between vascular, metabolic and clinical factors, and cognitive performance in a cohort of adults with severe obesity. Consistent with our previous reports, we hypothesize higher BMI values to be associated with lower cognitive performance. We also hypothesize various conditions linked to obesity (e.g., diabetes, hypertension) adversely impact brain function in individuals with severe obesity.

Method {#S7}
======

Study Design {#S8}
------------

This current study employed data from the University of Florida's Weight Loss Intervention and Surgical Effects (WISE) study. Funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), this longitudinal R01 study examines the effects of severe obesity on cognition and brain functioning to determine if weight loss occurring following bariatric surgery contribute to improvements in cognition that can be attributed to specific metabolic, vascular, and neural changes occurring in the brain. The research described herein presents pre-surgical baseline data from a cohort of surgical and non-surgical participants who are being followed prospectively in this larger study.

Participants {#S9}
------------

Individuals aged 20--75 years (with BMI ≥ 35kg/m^2^) were eligible to participate in the study. Exclusion criteria included total score \< 20 on the Montreal Cognitive Assessment (MoCA), history of neurological disorder or injury, severe psychiatric illness, unstable medical condition (e.g., cancer), and history of alcohol or substance abuse. 129 patients were assessed at baseline. 65.9% met criteria for Class III obesity (BMI ≥ 40.0) while 34.1% were Class II (BMI of 35.0 -- 39.9). The sample included bariatric surgery candidates (n = 88), and community dwellers with similar BMI levels who were not planning to have weight loss surgery. The community sample was recruited as controls for future analysis of post-operative changes in cognitive and brain functioning. Members from both groups reported history of diet-and-exercise methods of weight loss, but denied bulimia nervosa.

Procedures {#S10}
----------

The local Institutional Review Board (IRB) approved all study procedures, and all participants provided written, informed consent prior to enrollment. Participants completed a medical history evaluation, a neuropsychological assessment battery, and self-report questionnaires. In addition, participants underwent polysomnographic evaluation (if never assessed for OSA or not using CPAP therapy). A blood sample was collected for HbA1c determination. Fasting plasma glucose was also obtained from medical records for surgical participants.

Measures {#S11}
--------

### Demographic and Medical History. {#S12}

History of hypertension, type-2 diabetes, osteoarthritis, BMI, apnea, and CPAP therapy and pertinent demographic data were collected through medical chart review and a background history questionnaire. Premorbid intellect was measured using the Barona Index,^[@R21]^ an equation that uses the demographic variables (e.g., age, gender, education) to estimate an individual's intelligence quotient (IQ). Current depressive symptoms were reported via the Beck Depression Inventory -- 2^nd^ Edition.^[@R22]^ Fasting plasma glucose and Hemoglobin A1c (HbA1c) levels, which indicates average plasma glucose concentration, were measured, along with type of antidiabetic medications used. Per medical standards, HbA1c ≥ 6.5% or plasma glucose ≥ 126 mg/dL indicates diabetes.^[@R23]^

### Neuropsychological Measures. {#S13}

All participants underwent a brief neuropsychological battery to assess various aspects of cognition including attention, processing speed, memory, executive functioning, and verbal fluency. All measures used in the current study are well known for their strong psychometric properties. The domains and neuropsychological tests used are reported in [Table 1](#T1){ref-type="table"}.

Data Analysis. {#S14}
--------------

Demographic and clinical characteristics were evaluated with descriptive statistics. Chi-square analyses were used to compare concurrence of diagnosis with various biomarkers or treatment, such as incidence of diabetes diagnosis (hereafter "diabetes") and measured HbA1c levels, or history of apnea among individuals using CPAP therapy versus non-treatment. Similar analyses were conducted to assess CPAP use, HbA1c, and prevalence of medical comorbidities across obesity class. For subsequent analyses, the two groups were pooled since bariatric surgery effects were not being examined. Missing cognitive and medical data were excluded listwise.

Means, standard deviation, and cognitive performance rates were calculated for all individual cognitive performances along with mean T-scores for overall cognition, attention, verbal fluency, processing speed, memory, and executive functioning domains. We used chi-square analyses to determine if cognitive performances in specific domains were significantly different from normative expectations. Scores below the 16^th^ percentile (i.e., T-scores \< 40) were considered below average.

Two sets of regression analysis (backward elimination) were used to study clinical risk factors as predictors for various aspects of cognition. Overall cognitive domain composite scores were used in the first set of analyses, in which all raw data for included neuropsychological measures assessing cognition were transformed into T-scores (*M* = 50, *SD* = 10) using well-established normative data to control for age, education, and sex. Only age-corrected norms were available for Stroop and ARCPT measures; thus, education and sex were entered as covariates at the final step of regression analysis. Although all measures were controlled for age, additional t-tests helped assess potential group differences between young (ages 20--40) and older (41+) adults. Given recognized associations between depression and cognition, we also controlled BDI-2 total scores. The second set of analyses examined within-domain, individual neuropsychological test performances. Potential explanatory variables included BMI, HbA1c, and history of hypertension, diabetes, CPAP use, apnea, and osteoarthritis. Fasting plasma glucose was evaluated in a separate analysis, as data was available only for 30 pre-surgical participants.

Results {#S15}
=======

Demographic and clinical characteristics. {#S16}
-----------------------------------------

The majority of patients met criteria for severe obesity and a significant proportion of the total sample reported diagnosis of hypertension (57.4%), diabetes (35.7%), apnea (42.6%), and osteoarthritis (34.9%). The sample as a whole reported minimal to mild depressive symptoms on the BDI-II (*M* = 10.59, *SD* = 8.90). Participants had up to four comorbidities, and the majority of participants had at least one comorbidity (83.5%). Additional demographic and clinical data are presented in [Table 2](#T2){ref-type="table"}.

Correlation and cross-tabulation analyses were performed to characterize the study sample and examine relationships between medical variables of interest. Fasting glucose among surgical participants was positively associated with HbA1c (*r* = .86, p \< .001) and diabetes (*r* = .58, p \< .001). Diabetes and HbA1c were also strongly associated (*r* = .76, χ^2^\[1, 100\] = 58.01, p \< .001.) However, only 4 of 46 participants with diabetes exhibited HbA1c levels below the standard cutoff (HbA1c \< 6.5), while 88.2% of participants with diabetes showed elevated HbA1c despite control with diet or medication. Metformin (56%) and insulin (28%) were the most commonly used antidiabetic medications. Seven individuals with no record of diabetes had elevated HbA1c (≥ 6.5). Additionally, rate of hypertension rate was 81.1% for individuals with elevated HbA1c, indicating a strong association between variables (*r* = .38, χ^2^\[1, 102\] = 14.95, p \< .001.) Osteoarthritis was also significantly higher among individuals with elevated HbA1c (51.4%) versus normal status (29.2%; *r* = .22, χ^2^\[1, 102\] = 4.94, p \< .05.)

Despite a strong association between CPAP use and sleep apnea, there was not a complete correspondence between diagnosis and treatment as only 51.9% of those with apnea reported using CPAP intervention (*r* = .55, χ^2^\[1, 128\] = 38.34, p \< .001.) There was also a higher than expected number of individuals with apnea also diagnosed with diabetes (*r*=.17, χ^2^\[1, 129\] = 3.82, p = .05). No other associations were found for other clinical variables.

Neurocognitive performance {#S17}
--------------------------

All cognitive domain scores were in the average range, but below expectancy based on the participants' estimated pre-morbid intelligence (BARONA T-score: *M* = 52.55, *SD* = 5.76). Global cognition was .41 SD below premorbid estimates; *t*(67) = 4.40, p = .02. Participants did not exhibit severe neurocognitive disturbances (i.e., scores greater than two standard deviations below the normative mean); deficits for individual cognitive domains ranged from −.25 to −1.15 SDs. Statistically significant deficits (p \<. 05) relative to premorbid estimates were evident for verbal fluency, memory, processing speed, and executive functioning domains.

Cognitive performances did not differ significantly between young and older participants across most cognitive domains or individual test scores. Age-associated differences were evident in two cognitive domains (Attention; *t*\[76\] = −2.14, p = .04; Memory: ; *t*\[115\] = −2.04, p = .04) and two individual test scores contributing to these domains (ARCPT sensitivity a'; *t*\[76\] = - 77, p \< .001; CVLT-II delayed recall; *t*\[116\] = −2.62, p = .01). However, for each of these measures, older participants performed better than younger participants, indicating that older age was not associated with greater obesity-related cognitive deficits.

Across the sample, performance was greater than one standard deviation below the normative average in two cognitive domains; Processing Speed (χ^2^\[1, 124\] = 12.03, p \< .01) and Executive Functioning (χ^2^\[1, 126\] = 4.62, p \< .05). Individual test performances contributing to these domains were also significantly lower than expected, though there were also decrements for various outcomes on ARCPT, CVLT-II, and letter fluency measures.

Clinical factors associated with cognitive performance. {#S18}
-------------------------------------------------------

Regression analyses were performed to assess relationships between BMI, each comorbidity, and neurocognitive performance ([Table 4](#T4){ref-type="table"}). In the first analysis, we examined the relationship of clinical factors with the overall cognition composite and performance within each cognitive domain. The same clinical factors were also examined relative to individual neuropsychological test performances that contributed to each domain score.

Diabetes and HbA1c were the clinical factors associated with performance in the majority of cognitive domains. HbA1c was associated with overall cognitive performance (β = −.44, p = .002). BMI was significantly associated with reduced performance in the verbal fluency domain only. The relationships between clinical factors and performance in each cognitive domain are described below.

### Attention. {#S19}

HbA1c was associated with performance in the attention domain (β = −.29, p = .03). Fasting plasma glucose in surgical participants was also related to attention (β = −.49, p = .01). Analysis of ARCPT sub-indices indicated that the Inconsistency Index score was related to BMI (β = −.31, p = .02) and Final ISI was related to HbA1c blood levels (β = −.38, p = .004). No associations were found for accuracy in detection of targets (Sensitivity a').

### Processing Speed. {#S20}

Diabetes was associated with slower performance in the processing speed domain (β = −.21, p = .05). Secondarily, diabetes was associated with speed of both word reading (β = −.23, p = .05) and color naming (β = −.23, p = .03) on the Stroop task. Trail Making Part A completion time was not significantly associated with any clinical factor.

### Memory. {#S21}

Performance in the memory domain was associated with CPAP use (β = .38, p = .006). Participants who used CPAP had stronger CVLT-II total learning (β = .39, p = .006) and long delayed recall scores (β = .22, p = .04). Sleep apnea was inversely related to CVLT-II total learning (β = −.30, p = .03). BMI and other comorbidities were not significantly associated with learning or memory performance.

### Executive Functioning. {#S22}

Diabetes was associated with reduced performance in the executive domain (β = −.23, p = .03) and weaker executive performance on the Trail Making Part B task (β = .21, p = .04). Performance on the Stroop Color-Word inhibition trial was not associated with any clinical variables.

### Verbal Fluency. {#S23}

Elevated BMI was associated with lower verbal fluency performance (β = −.24, p = .02). In secondary analysis, semantic fluency (animal naming) was most strongly associated with diabetes (β = −.25, p = .02), but not letter fluency performance.

Discussion {#S24}
==========

The current findings provide further evidence of a relationship between obesity and reduced cognitive performance. In this cohort of adults with Class II and III obesity, deficits in cognitive performance were found relative to the normative population and participants' own pre-morbid intelligence. These deficits did not appear to be age-associated as most participants were between the age of 30 and 55 and older participants did not perform worse for any cognitive outcomes when the cohort was dichotomized at 40 years of age.

These results reinforce previous findings showing that elevated BMI is associated with reduced cognitive performance, and extend past findings to individuals with severe obesity. Although we did not observe, nor expect, severe cognitive dysfunction among participants, overall cognitive performance was approximately 0.5 SD below estimated premorbid intellect for the sample, and a significant proportion exhibited performance in the executive and processing domains that was greater than 1 SD below normative levels.

Consistent with the study hypotheses, comorbid conditions were significantly associated with cognitive performance. Diabetes most strongly and consistently associated with neurocognitive performance, for both the total cognitive composite score and specific cognitive domains. The diabetes measure with the strongest association to these cognitive domains varied. Diabetes diagnosis was most strongly associated with reduced overall cognitive performance, and deficits in the executive, processing speed, and verbal fluency domains, whereas elevated HbA1c was associated with reduced attentional performance. The exception was the Memory domain, as OSA diagnosis and CPAP were most strongly associated with learning and memory recall.

Thus, comorbidities occurred in the context of severe obesity with a restricted BMI range, and the results must be interpreted in this context. Notably, BMI was not among the clinical factors associated with overall cognitive performance, nor deficits in the Executive, Processing Speed, and Memory domains. Yet, elevated BMI was associated with variability in sustained attention on the ARCPT. Its association with reduced verbal fluency performance is also noteworthy as these tasks require sustained attention or response generation with effortful demands that may be more taxing with greater BMI, even in the context of severe obesity. Given that obesity is disproportionately higher with lower income and education, limited vocabulary can influence verbal fluency scores; however, this is unlikely for this cohort as BARONA values were not significantly related to BMI or verbal fluency. Additionally, most investigations into the relation between SES/education and cognitive function have not controlled for confounding health and behavioral factors.^[@R24]^

Comparisons between Class II and III participants failed to show differences on any of the cognitive measures. While, counter to our original hypotheses, the extent of BMI elevation may be less determinant of the severity of cognitive deficits in the context of severe obesity than the impact of comorbidities, particularly diabetes. This should not be interpreted as an indication that elevated BMI did not affect cognitive performance. Very elevated BMI was ubiquitous in the cohort with a mean BMI of 45, and the influence of BMI on cognitive performance was likely relatively consistent, such that the added adverse impact of comorbidities is evident. Therefore, among adults with severe obesity, BMI may be a less sensitive indicator of cognitive dysfunction than is the presence of comorbidities such as diabetes.

That diabetes was the factor most strongly associated with both overall cognitive performance and deficit across multiple cognitive domains is not surprising. There is mounting evidence that diabetes plays a significant role in brain pathophysiology, and in the development of stroke, other cerebrovascular disturbances, Alzheimer's disease and neurodegeneration. Diabetes can affect the brain in a number of different ways. Insulin resistance causes alterations in the liver-brain axis that results in the production of toxic lipids and ceramides which in turn can cause oxidative stress, neuroinflammation, and possibly cell death and neurodegeneration.^[@R25]^ Insulin resistance also causes endothelial damage, which can alter blood vessel integrity and cause other vascular abnormalities.^[@R26]^ In addition to increased risk of stroke among people with uncontrolled diabetes, microvascular disturbances often occur, resulting in the accumulation cerebral white matter lesions^[@R27]^ and subsequent cognitive dysfunction.^[@R28]^ These pathophysiological mechanisms may account for the observed associations between diabetes and cognitive deficits the attention, executive, processing speed and verbal fluency domains. These cognitive functions tend to be particularly vulnerable to microvascular and hemodynamic alterations that affect cerebral white matter and frontal-subcortical systems.^[@R29]^

The observed relationship between OSA and verbal learning performance supports past findings that chronic sleep apnea contributes cognitive and brain dysfunction.^[@R30]^ Participants who used CPAP for OSA actually had stronger verbal learning and delayed recall on the CVLT-II. This finding is also consistent with previous findings of CPAP adherence being associated with improved learning and memory.^[@R31]^ It is possible that adverse cognitive effects of OSA were mostly mitigated by CPAP, or that participants who adhered to CPAP had stronger pre-morbid cognitive ability contributing to better CPAP adherence.^[@R32],[@R33]^ Hypertension could also contribute to similar adverse effects on the brain,^[@R34],[@R35]^ though in the current study, hypertension was not associated with deficits in any cognitive domain. When hypertension has been examined in clinical populations consisting of more severe forms of cerebrovascular or cardiovascular disease (e.g., heart failure), its adverse impact on the cognition and the brain is often masked by other etiological factors, such as the presence of systemic hypoperfusion.^[@R36]^ In the current study, almost all participants with a diagnosis of hypertension were pharmacologically treated, with relatively well-controlled blood pressure. Osteoarthritis was also not found to contribute to obesity-associated deficits in this cohort even though it causes systemic inflammation,^[@R37]^ which can affect cognitive functioning.

Several factors may explain why these certain cognitive functions are particularly vulnerable to these pathophysiological processes: 1) Processing speed deficits result from reduced neural transmission efficiency secondary to white matter damage;^[@R36]^ 2) Highly metabolic frontal-subcortical systems responsible for attention-executive functions, processing speed, and working memory are more vulnerable to hypoperfusion;^[@R36],[@R38]^ 3) Executive-attention and controlled 'top-down' processes are more susceptible to effortful demands and involve the integration of multiple cognitive skills^[@R39]^ than are 'bottom-up' cognitive functions like perception; Obesity and its comorbidities tend not to cause focal abnormalities, thus certain brain functions (e.g., language, memory, sensory-perceptual) that are more topographically restricted may be less common with vascular cognitive impairment and metabolic disturbances.

There are several limitations regarding conclusions that can be drawn from this study. The reported results came from cross-sectional analyses of baseline cognitive functioning. Causality cannot be inferred based on the observed associations between the clinical factors and cognition. While medical record and detailed medical history data was available on all clinical measures, the diagnoses of hypertension, OSA, and arthritis were coded categorically. For example, OSA diagnosis was determined on the basis of medical record review, self-report, and polysomnogram results when possible. However, not all participants had data from each of these three sources, which could have resulted in some imprecision in the determination of OSA severity. Data was not available regarding date of onset of medically diagnosed obesity, so that it is not possible to determine the extent to which duration or age of onset of obesity contributed to the observed relationships.

While intuitively one might expect BMI to be strongly associated with cognitive performance, the fact that this was not the case for most cognitive domains is not surprising in light of considerations discussed earlier. However, it is possible that other methods for quantifying obesity (e.g., waist circumference, body fat composition) could prove to be more sensitive to cognition. Unfortunately, these measures were not consistently available in the study. Finally, it should be emphasized that to some extent the data that was collected was constrained by the standard clinical procedures employed by the bariatric surgery team. Additional laboratory measures would have been of analytic interest, but could not be obtained routinely. For example, hbA1C was determined from acquired blood samples, and fasting glucose values were available for few participants. However, fasting insulin was not, so a homeostatic model assessment (HOMA) index could not be obtained in a sufficient number of participants to enable examination of the contribution of insulin resistance (HOMA-IR) which might provide greater sensitivity to obesity-associated cognitive deficits. Despite known drawbacks,^[@R40]^ there would be benefit in obtaining this metric in future studies.

Conclusion {#S25}
==========

Compelling evidence of cognitive deficits among adults with severe obesity in the current study provides support for and extends past findings of a relationship between elevated BMI and reduced cognitive performance. The deficits observed in the study cohort were greatest with respect to executive functioning and cognitive processing speed relative to both normative data and pre-morbid intelligence. As expected, comorbidities known to be common with severe obesity were very prevalent in the study cohort. Type-2 diabetes was the comorbidity most strongly and consistently associated with cognitive deficits, while obstructive sleep apnea was associated with learning and memory performance. Counter to expectation, BMI was not significantly associated with overall cognitive performance or with deficits in most cognitive domains. This is probably attributable to the restricted range of BMI in this sample of adults with Class II and III obesity. Nonetheless, this finding suggests that in the context of severe obesity, the presence of comorbidities such as diabetes takes on greater significance by adversely affecting cognitive functioning.

The current study is only one step towards disentangling these complex influences. While the association of diabetes or other comorbidities to cognitive deficits gives clues to possible underlying pathophysiological mechanisms, other types of data are needed to adequately address these questions. Incorporating neuroimaging methods along with cognitive measures may help this effort. Multimodal neuroimaging is well suited in this regard, making it possible to simultaneously measure alterations in cerebral neural response with functional MRI, abnormal cerebral metabolite concentrations via magnetic resonance spectroscopy, reductions in cerebral blood flow using MRI methods such as arterial spin labeling, and the existence of neuroinflammation based on concentrations of extracellular free-water from diffusion imaging. As longitudinal data becomes available from the current study cohort following bariatric surgery, we will also be able to examine causal relationships to a greater extent by determining the relationship between improvements in BMI, diabetes status, and other comorbidities with changes in cognition. We will also examine changes that occur in the brain following bariatric surgery by analyzing data from multimodal neuroimaging.

Individual participant data will not be available as the data are still being collected as part of an active R01 study, and are thus restricted for sharing.
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###### 

Neuropsychological Test Measures

  Test Measure               Test Description
  -------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Attention                  
  *ARCPT Inconsistency*      Computerized measure of vigilance and sustained attention. Participants respond through a single keystroke when a specific combination of letters appears on the screen. Indices examined included *inconsistency*, *final ISI* (i.e., the minimum interval between stimulus items ISI at which participants can maintain 80% accuracy), and *sensitivity a'* (i.e., accuracy in detecting hit targets).
  *ARCPT Final ISI*          
  *ARCPT Sensitivity a'*     
                             
  Processing Speed           
  *TMT Part A*               Assessment of visual search speed requiring examinee to draw a continuous line through 25 consecutive numbered circles; performance is measured by overall completion time.
  *Stroop Word Reading*      Measures selective attention, cognitive speed, and response inhibition.
  *Stroop Color Naming*      The test includes two baseline trials lasting 45 seconds each. Trial I (Word Reading) consists of 100 randomly arranged words (RED, GREEN, and BLUE) that the participant must quickly read aloud. In Trial II (Color Naming), the participant quickly names color patches.
                             
  Memory                     
  *CVLT-II Total Recall*     Requires learning and recall of a 16-item word list. After the initial learning phase, participants are asked to recall the list after a 20-minute delay. Indices examined included total recall (trials 1--5) and long delay free recall.
  *CVLT-II Long Delay*       
                             
  Executive Functioning      
  *Stroop Color-Word*        Contains colored words in which the word and the color do not match. This test provides a measure of 'cognitive inhibition in terms of the ability to inhibit a pre-potent response (reading the word) in favor of naming the ink color.
  *TMT Part B*               Requires that the examinee draw a continuous line through consecutive numbers and letters, alternating the order each time a connection is made (i.e., 1-A-2-B-3-C, etc.). Unlike Part A, this task introduces the added cognitive demand of mental set-shifting.
                             
  Verbal Fluency             
  *Letter Fluency (COWAT)*   Speeded word-retrieval based on letter cues. Performance based on total number of correct responses.
  *Animal Fluency*           Rapid word generation for a semantic category. Performance based on total number of correct responses.
                             
  Overall Cognition          Composite score generated using aggregate data from the above individual domains.

*Note*. ARCPT = Adaptive Rate Continuous Performance Test^[@R41]^; TMT = Trail-Making Test^[@R42]^; Stroop = Stroop Color-Word Test^[@R43]^; CLVT-II = California Verbal Learning Test -- 2^nd^ Edition (CVLT-II)^[@R44]^ Verbal Fluency = Controlled Oral Word Association (COWAT) and Semantic fluency (Animals)^[@R45]^

###### 

Demographic and clinical characteristics of total sample (continuous variables reported as mean ± SD, and categorical variables as percentages)

  Characteristic                                           Total sample (N = 129)
  -------------------------------------------------------- ------------------------
  Age (yr)                                                 45.65 ± 12.41
  Gender (% women)                                         73.6
  Education (yr)                                           13.72 ± 2.53
  Race (% Caucasian)                                       64.3
  Number of comorbidities (%)                              
    None                                                   17.1
    One                                                    24.0
    Two                                                    20.9
    Three                                                  20.2
    Four                                                   17.9
  Hypertension (%)                                         57.4
  BMI (kg/m^2^)                                            45.42 ± 8.28
  Class Obesity (%)                                        \--
    Class II                                               33.8
    Class III                                              65.4
  Type-2 diabetes (%)                                      35.7
    Controlled with diet (% \[n\])                         19.6 (9)
    On oral anti-diabetic medication (% \[n\])             43.5 (20)
    On insulin only (% \[n\])                              15.2 (7)
    On oral anti-diabetic medication & insulin (% \[n\])   17.4 (8)
    Not reported (% \[n\])                                 10.9 (5)
  Fasting plasma glucose (mg/dL)                           120.5 ± 54.03
  HbA1c                                                    6.44 ± 1.46
    Normal (% \[n\])                                       33.1
    Elevated (% \[n\])                                     36.6 (37)
  CPAP use (%)                                             25.0
  Sleep apnea (%)                                          42.6
  Arthritis (%)                                            34.9

*Note*: BMI = body mass index; CPAP = continuous positive airway pressure.

T-scores have a mean of 50 and a standard deviation of 10.

###### 

Cognitive performances for the total sample (*N* = 129)

  Neurocognitive Domain          T-score Mean (SD)   \% \< 40 T-score   χ^2^
  ------------------------------ ------------------- ------------------ -----------------------------------------
  Overall Cognition              48.02 ± 6.31        8.8                1.78
  Attention                      50.55 ± 14.86       15.4               .02
  Processing Speed               45.13 ± 7.67        27.4               12.03[\*\*](#TFN6){ref-type="table-fn"}
  Memory                         49.76 ± 10.01       14.5               .19
  Executive Functioning          46.97 ± 8.81        23.0               4.62[\*](#TFN5){ref-type="table-fn"}
  Verbal Fluency                 47.22 ± 7.50        18.4               .38
                                                                        
  Neuropsychological Measure     T-score Mean (SD)   \% \< 40 T-score   χ^2^
                                                                        
  ARCPT Inconsistency            46.56 ± 16.39       26.6               5.39[\*](#TFN5){ref-type="table-fn"}
  ARCPT Final ISI                47.48 ± 25.61       25.3               5.34[\*](#TFN5){ref-type="table-fn"}
  ARCPT Sens A'                  57.60 ± 9.89        6.3                5.37[\*](#TFN5){ref-type="table-fn"}
  Stroop Color Naming            43.19 ± 10.02       42.2               63.69[\*\*](#TFN6){ref-type="table-fn"}
  Stroop Word Reading            41.95 ± 7.93        41.7               57.20[\*\*](#TFN6){ref-type="table-fn"}
  Stroop Color-Word Inhibition   45.45 ± 9.90        32.8               25.65[\*\*](#TFN6){ref-type="table-fn"}
  CVLT Total Recall              50.47 ± 10.19       16.0               .05
  CVLT Long Delay Recall         49.11 ±11.61        28.6               12.57[\*\*](#TFN6){ref-type="table-fn"}
  Trail Making Test: Part A      50.29 ± 12.31       19.5               1.38
  Trail Making Test: Part B      48.46 ± 10.80       18.8               .79
  Letter Fluency (FAS)           46.74 ± 9.20        30.5               18.80[\*\*](#TFN6){ref-type="table-fn"}
  Category Fluency (Animals)     47.80 ± 9.14        17.3               .06

*Note*.

*p* \< .05,

*p* \< .001.

T-scores have a mean of 50 and a standard deviation of 10.

###### 

Relationships between clinical factors and individual cognitive performances (*N* = 129)

  Cognitive Domain          Test Measure   Clinical Variable                         β
  ------------------------- -------------- ----------------------------------------- -----------------------------------------
  *Overall Cognition*                      HbA1c                                     −.44[\*\*](#TFN10){ref-type="table-fn"}
                                                                                     
  *Attention*                              HbA1c                                     −.29[\*](#TFN9){ref-type="table-fn"}
  ARCPT Inconsistency       BMI            −.31[\*](#TFN9){ref-type="table-fn"}      
  ARCPT Final ISI           HbA1c          −.38[\*\*](#TFN10){ref-type="table-fn"}   
  ARCPT Sensitivity a'                     *ns*                                      
                                                                                     
  *Processing Speed*                       Diabetes                                  −.21[\*](#TFN9){ref-type="table-fn"}
  Trail Making Part A                      *ns*                                      
  Stroop Word Reading       Diabetes       −.23[\*](#TFN9){ref-type="table-fn"}      
  Stroop Color Naming       Diabetes       −.23[\*](#TFN9){ref-type="table-fn"}      
                                                                                     
  *Memory*                                 CPAP                                      .38[\*\*](#TFN10){ref-type="table-fn"}
  CVLT-II Total Recall      CPAP           .39[\*](#TFN9){ref-type="table-fn"}       
                            Apnea          −.30[\*](#TFN9){ref-type="table-fn"}      
  CVLT-II Long Delay        CPAP           .22[\*](#TFN9){ref-type="table-fn"}       
                                                                                     
  *Executive Functioning*                  Diabetes                                  −.23[\*](#TFN9){ref-type="table-fn"}
  Stroop Color-Word                        *ns*                                      
  Trail Making Part B       Diabetes       −.21[\*](#TFN9){ref-type="table-fn"}      
                                                                                     
  *Verbal Fluency*                         BMI                                       −.24[\*](#TFN9){ref-type="table-fn"}
                            Diabetes       −.21[\*](#TFN9){ref-type="table-fn"}      
  Letter Fluency                           *ns*                                      
  Animal Fluency            Diabetes       −.25[\*](#TFN9){ref-type="table-fn"}      

*Note*.

*p* \< .05,

*p* \< .01;

*ns* = not significant at *p* \< .05 level or below. T-scores have a mean of 50 and a standard deviation of 10. Normative data was used to adjust for age, education, and sex for Trail Making Test, CVLT-II, and verbal fluency measures. For Stroop and ARCPT measures, used only age-corrected normative data; thus, education and sex were entered as co-variates into the regression models (final step).

###### Study Importance

-   The study findings provide evidence of cognitive deficits associated with obesity relative to both normative data and estimated pre-morbid intelligence. These results reinforce previous findings by our group and others showing reduced cognitive performance among adults with elevated BMI, and extend past findings to individuals with severe obesity (Class II and Class III)

-   This is among the few studies to simultaneously examine the contribution of multiple comorbid risk factors and etiologies to cognitive performance in severe obesity. Consistent with the study hypotheses, comorbidities common among adults with severe obesity were significantly associated with cognitive performance. The presence of diabetes, including elevations in laboratory biomarkers of diabetes (HbA1c, fasting glucose) were most strongly and consistently associated with reduced cognitive performance (total cognitive composite score, attention, executive functioning, processing speed, and verbal fluency.) The one exception was for the memory domain, in which obstructive sleep apnea diagnosis and CPAP use were the factors most strongly associated with performance.

-   Body mass index (BMI), which was used for categorizing severe obesity class, was not among the clinical factors associated with overall cognitive performance, and was not consistently associated with deficits across specific cognitive domains. BMI was not associated with performance in the Executive, Processing Speed, and Memory domains, yet BMI along with diabetes diagnosis were associated most strongly with sustained attention performance.

-   The findings suggest that in the context of severe Class II and Class III obesity, comorbidities, especially diabetes, make significant contributions to cognitive dysfunction, while the contribution of elevated BMI is less apparent. The fact that BMI was not found to be strongly associated with cognitive performance overall or in most domains, is likely because elevated BMI was ubiquitous in the cohort, with participants having a BMI \> 35. At these elevated levels, comorbidities may have greater added impact, and BMI may become a less sensitive indicator of cognitive function. It is also important to note that the comorbidities evident in this cohort occurred against the backdrop of severe obesity, such that elevated BMI exerts a relatively constant influence, compounded by the presence of diabetes or other comorbidities.
